FDA turns a blind eye to Yaz and Yazmin’s Dangers

The Yaz law suits have created a nightmare for its victims and the United States Food and Drug Administration (FDA) that is supposed to be safeguarding Americans taking this dangerous medication.

Last month an advisory panel for the FDA recommend that the benefits of Yaz, Yasmin, Beyaz and Safyral made with the synthetic progestin, drospirenone, outweighed the risk of developing a life threatening and dangerous blood clot. Apparently, three of the “FDA’s advisers” are closely tied to Bayer AG, the maker of the drugs. For some reason, the FDA forgot to disclose this key fact.

The Wall Street Journal, (WSJ) reported that the advisers are, Julia V. Johnson of the University of Massachusetts Medical School, Paula Hillard, an obstetrics professor at Stanford University School of Medicine and Anne E. Burke, professor of gynecology and obstetrics at Johns Hopkins. All of whom have done research for and funded by Bayer.

As a Miami Yaz claims attorney I don’t understand how the FDA could even allow these three to vote on an issue that they are clearly partial to. According to the WSJ, the “Lack of disclosure undermines the credibility of the advisory committee process and undermines public trust in the fairness of the regulatory process.”

Dr. Sidney Wolfe of the consumer group Public Citizen, was stripped of his voting rights by the FDA because he had publicly criticized the drugs’ safety in newsletters published by the group. How is that fair?

This type of favoritism is another example of how our government conceals the dangers of products from consumers and allows dangerous medications to be consumed by an unsuspecting and trusting public. Is it any wonder that the general public has lost faith in its government, particularly when the powerful pharmaceutical to essentially serve as its own judge and jury? The FDA allows dangerous drugs to be marketed and tested on an a public who believe that the FDA does more than rubber stamp drugs before they are approved.